Bennett Shapiro , Board Chair, Drugs for Neglected Diseases Initiative (DNDi) North America
Bennett Shapiro is a Senior Partner and Chair of PureTech Ventures. Prior to this, he was Executive Vice President, Worldwide Licensing and External Research, where he directed all of Merck’s research relationships with the academic and industrial biomedical research community. He joined Merck in
September of 1990 as Executive Vice President, Basic Research, Merck Research Laboratories, where he was responsible for all the basic and preclinical research activities at Merck worldwide.
Earlier, he was Professor and Chairman of the Department of Biochemistry at the University of Washington. He is the author of over 120 papers on the molecular regulation of cellular behavior and the biochemical events that integrate the cascade of cellular activations at fertilization.
Shapiro received his bachelor’s degree in chemistry from Dickinson College and his doctor’s degree in medicine from Jefferson Medical College. Following an Internship in Medicine at the University of Pennsylvania Hospital, he was a Research Associate at the NIH, then a Visiting Scientist at the Institut Pasteur in Paris and returned to the NIH as Chief - Section on Cellular Differentiation in the Laboratory of Biochemistry, prior to joining the University of Washington. Dr. Shapiro has been a Guggenheim Fellow, a Fellow of the Japan Society for the Promotion of Science and a Visiting Professor at the University of Nice. He has served on many institutional advisory boards and scientific review panels. He is currently Chair of VBL therapeutics, and on the Board of Directors of Momenta Pharmaceuticals and the Drugs for Neglected Diseases initiative, as well as biotech startups Satori, Akili, and Vedanta.